Exisulind and Related Compounds Inhibit Expression and Function of the Androgen Receptor in Human Prostate Cancer Cells

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4972-4982

  Lim, Jin T E ^a   Piazza, Gary A ^b   Pamukcu, Rifat ^c   Thompson, W Joseph ^c   Weinstein, I Bernard ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c Cell Pathways Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CP 248; CP 461; LUCIFERASE; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL FUNCTION; DRUG EFFECT; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONE DEPENDENCE; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CELL LINE, TUMOR; DOWN-REGULATION; GENES, REPORTER; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; LUCIFERASES; MALE; MUTATION; NEOPLASM TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULINDAC; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0142219316     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Zerhouni, E. Prostate Cancer Res. Plan; FY 2003-FY 2008. pp. 1-50. Bethesda: NIH, 2002.
2. Kantoff, P., Giovannucci, E., and Brown, M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim. Biophys. Acta, 1378: C1-C5, 1998.
3. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science (Wash. DC), 240: 889-895, 1988.
4. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.
5. Labrie, F., Dupont, A., Belanger, A., St-Arnaud, R., Giguere, M., Lacourciere, Y., Emond, J., and Monfette, G. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr. Rev., 7: 67-74, 1986.
6. Kallioniemi, O. P., and Visakorpi, T. Genetic basis and clonal evolution of human prostate cancer. Adv. Cancer Res., 68: 225-255, 1996.
7. Housby, J. N., Cahill, C. M., Chu, B., Prevelige, R., Bickford, K., Stevenson, M. A., and Calderwood, S. K. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine, 11: 347-358, 1999.
8. Thompson, W. J., Piazza, G. A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D., and Pamukcu, R. Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res., 60: 3338-3342, 2000.
9. Lim, J. T., Piazza, G. A., Han, E. K., Delohery, T. M., Li, H., Finn, T. S., Buttyan, R., Yamamoto, H., Sperl, G. J., Brendel, K., Gross, P. H., Pamukcu, R., and Weinstein, I. B. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol., 58: 1097-1107, 1999.
10. Goluboff, E. T., Shabsigh, A., Saidi, J. A., Weinstein, I. B., Mitra, N., Heitjan, D., Piazza, G. A., Pamukcu, R., Buttyan, R., and Olsson, C. A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology, 53: 440-445, 1999.
11. Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res., 57: 714-719, 1997.
12. Han, E. K., Lim, J. T., Arber, N., Rubin, M. A., Xing, W. Q., and Weinstein, I. B. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate, 35: 95-101, 1998.
13. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. Lncap model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
14. Newling, D. W. The palliative therapy of advanced prostate cancer. with particular reference to the results of recent European clinical trials. Br J. Urol., 79 (Suppl. 1): 72-81, 1997.
15. Newling, D. W. Second-line treatment of metastatic prostatic carcinoma. Urol. Res., 25 (Suppl. 2): S73-S78, 1997.
16. Rennie, P., Bruchovsky, N., Leco, K., Sheppard, P., Mcqueen, S., Cheng, H., Block, M., Macdonald, B., Nickel, B., Chang, C., Liao, S., Cattini, P., and Matusik, R. Characterization of two cis-acting elements involved in the androgen regulation of the probasin gene. Mol. Endocrinol., 5: 1921-1930, 1993.
17. Dodd, J., Sheppard, P., and Matusik, R. Characterization and cloning of rat dorsal prostate mRNAs. J. Biol. Chem., 258: 10731-10737, 1983.
18. Beaulieu, M., Levesque, E., Tchernof, A., Beatty, B. G., Belanger, A., and Hum, D. W. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol., 16: 1143-1154, 1997.
19. Hartig, P. C., Bobseine, K. L., Britt, B. H., Cardon, M. C., Lambright, C. R., Wilson, V. S., and Gray, L. E., Jr. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol. Sci., 66: 82-90, 2002.
20. Wilson, V. S., Bobseine, K., Lambright, C. R., and Gray, L. E., Jr. A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol. Sci., 66: 69-81, 2002.
21. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31: 2393-2399, 1992.
22. Mizokami, A., Yeh, S. Y., and Chang, C. Identification of 3′, 5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol. Endocrinol., 8: 77-88, 1994.
23. Huang, C., Bode, A. M., Chen, N. Y., Ma, W. Y., Li, J., Nomura, M., and Dong, Z. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res., 21: 261-267, 2001.
24. Soh, J. W., Mao, Y., Kim, M. G., Pamukcu, R., Li, H., Piazza, G. A., Thompson, W. J., and Weinstein, I. B. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of e-Jun NH2-terminal kinase 1. Clin. Cancer Res., 6: 4136-4141, 2000.
25. Hackstein, H., Morelli, A. E., Larregina, A. T., Ganster, R. W., Papworth, G. D., Logar, A. J., Watkins, S. C., Falo, L. D., and Thomson, A. W. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol., 166: 7053-7062, 2001.
26. Yu, D. C., Sakamoto, G. T., and Henderson, D. R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res., 59: 1498-1504, 1999.
27. Sato, N., Sadar, M. D., Bruchovsky, N., Saatcioglu, F., Rennie, P. S., Sato, S., Lange, P. H., and Gleave, M. E. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem., 272: 17485-17494, 1997.
28. Sadar, M. D. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem., 274: 7777-7783, 1999.
29. Soh, J. W., Mao, Y., Liu, L., Thompson, W. J., Pamukcu, R., and Weinstein, I. B. Protein kinase G activates the JNKI pathway via phosphorylation of MEKK1. J. Biol. Chem., 276: 16406-16410, 2001.
30. Pilat, M. J., Kamradt, J. M., and Pienta, K. J. Hormone resistance in prostate cancer. Cancer Metastasis Rev., 17: 373-381, 1998.
31. Zhu, W., Smith, A., and Young, C. Y. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology, 140: 5451-5454, 1999.
32. Thalmann, G. N., Sikes, R. A., Chang, S. M., Johnston, D. A., von Eschenbach, A. C., and Chung, L. W. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [see comments]. J. Natl. Cancer Inst. (Bethesda), 88: 794-801, 1996.
33. Whitehead, C. M., Earle, K. A., Fetter, J., Xu, S., Hartman, T., Chan, D. C., Zhao, T. L., Piazza, G., Klein-Szanto, A. J., Pamukcu, R., Alila, H., Bunn, P. A., Jr., and Thompson, W. J. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol. Cancer Ther., 2: 479-488, 2003.
34. Piazza, G. A., Rahm, A. L., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukcu, R., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
35. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
36. Piazza, G. A., Fryer, B. H., Stolk, R. U. v., Budd, G. T., Stoner, G. D., Hawk, E., Kelloff, G., Pamukcu, R., Ahnen, D. J., and Ganapathi, R. Selective apoptosis of neoplastic cells accompanies polyp regression in familial adenomatous poplyposis (FAP) patients treated with FGN-I (sulindac sulfone): evidence for a cyclooxygenase independent mechanism. Gastroenterology, A-283, 1997.
37. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R., and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst. (Bethesda), 87: 1259-1260, 1995.
38. Goluboff, E. T., Prager, D., Rukstalis, D., Giantonio, B., Madorsky, M., Barken, I., Weinstein, I. B., Partin, A. W., and Olsson, C. A. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol., 166: 882-886, 2001.